Used in pharmaceutical research as a covalent inhibitor targeting Bruton's tyrosine kinase (BTK), particularly in the development of treatments for autoimmune diseases and certain B-cell malignancies. Its acrylate group enables irreversible binding to cysteine residues in BTK, enhancing prolonged inhibition. The compound is investigated for its potential in overcoming resistance mutations seen with reversible inhibitors. It serves as a key intermediate in synthesizing targeted therapies with improved selectivity and pharmacokinetic profiles.